ANAVEX2-73-RS-003 is a Phase 2/3, Double-blind, Randomized, Placebo-controlled Safety and Efficacy Study in Pediatric Patients With RTT Actual Study Start Date : July 1, 2020 Estimated Primary Completion Date : April 30, 2023 Last Participant Last Visit Estimated Study Completion Date : June 1, 2023